Crystalline and amorphous forms of a δ-opioid modulator
The present disclosure provides novel crystalline forms of a compound that acts as a δ-opioid effector, processes for preparing and precipitating amorphous and crystalline forms of the compound, and uses thereof.
1 . A crystalline Form I of (−)-6-{[(trans, trans)-4-[3-(2-methoxyethoxy)phenyl]-2-methyl-1-[2-(1H-pyrrol-1-yl)ethyl]piperidin-3-yl]methoxy}-2,3-dihydro-1H-isoindol-1-one having a formula of
wherein the crystalline Form I is characterized by an X-ray powder diffraction pattern comprising one or more peaks at about 18.3, at about 17.1, at about 17.3, at about 21.2, and at about 14.0±0.5 degrees 2θ.
2 . A crystalline Form I of (−)-6-{[(trans, trans)-4-[3-(2-methoxyethoxy)phenyl]-2-methyl-1-[2-(1H-pyrrol-1-yl)ethyl]piperidin-3-yl]methoxy}-2,3-dihydro-1H-isoindol-1-one having a formula of
wherein the crystalline Form I is characterized by an X-ray powder diffraction pattern comprising one or more peaks as shown in FIG. 16 .
3 . The crystalline Form I of claim 1 characterized by an X-ray powder diffraction pattern comprising one or more d-spacing values at about 6.3, at about 5.1, at about 5.2, at about 4.9, and at about 4.2±0.5 degrees angstroms.
4 . A pharmaceutical composition comprising the crystalline Form I of claim 2 and a pharmaceutically acceptable excipient.
5 . A pharmaceutical composition comprising the crystalline Form I of claim 1 and a pharmaceutically acceptable excipient.
6 . The pharmaceutical composition of claim 5 , further comprising an additional drug for the treatment of pain, migraine, headache, depression, Parkinson's disease, anxiety, overactive bladder, medication overuse headache, hyperalgesia, decreasing nociceptive sensitization, pain in an opioid exposed subject, PTSD other disorders and conditions described herein or any combination thereof.
7 . A process for preparing a crystalline form of the compound of Formula I, comprising crystallizing the crystalline form of the compound of Formula I and optionally isolating the crystalline form of the compound of Formula I.
8 . A method of alleviating the symptoms of or diminishing the extent of a condition, disorder, or disease selected from the group consisting of pain, neuropathic pain, migraine, headache, depression, Parkinson's disease, anxiety, overactive bladder, medication overuse headache, hyperalgesia, decreasing nociceptive sensitization, pain in an opioid exposed subject, and PTSD, or any combination thereof, the method comprising administering to a patient in need thereof, the crystalline Form I of claim 1 , or a pharmaceutical composition comprising the crystalline Form I of claim 1 and a pharmaceutically acceptable excipient.
9 . A method of treating hyperalgesia in a subject comprising administering to the subject comprising administering to a patient in need thereof, the crystalline Form I of claim 1 , or a pharmaceutical composition thereof and a pharmaceutically acceptable excipient.
10 . A method of decreasing nociceptive sensitization in a subject comprising administering to a patient in need thereof, the crystalline Form I of claim 1 , or a pharmaceutical composition thereof and a pharmaceutically acceptable excipient.
11 . A method of alleviating the symptoms of or diminishing the extent of pain in a subject comprising administering an opioid agonist to the subject until the opioid increases nociceptive sensitization in the subject and administering to a patient in need thereof, the crystalline Form I of claim 1 , or a pharmaceutical composition thereof and a pharmaceutically acceptable excipient.
12 . A method of alleviating the symptoms of or diminishing the extent of pain in an opioid exposed subject comprising:
a) administering an opioid agonist to the subject;
b) administering to the subject of step a), in the absence of the opioid administered in step a), the crystalline Form I of claim 1 or a pharmaceutical composition thereof and a pharmaceutically acceptable excipient.
13 . The method of claim 12 , wherein the opioid is morphine, oxycodone, hydrocodone, hydromorphone, fentanyl, meperidine, alfentanil, remifentanil, sufentanil, etorphine, buprenorphine, methadone, and/or heroin, or a pharmaceutically acceptable salt thereof.
14 . A method of alleviating the symptoms of or diminishing the extent of medication overuse headache in a subject comprising administering to a patient in need thereof, the crystalline Form I of claim 1 , or a pharmaceutical composition thereof and a pharmaceutically acceptable excipient.
15 . The method of claim 14 , wherein the medication overuse headache is caused by acetaminophen, aspirin, a mu-opioid agonist, a non-steroidal anti-inflammatory drug (NSAID), or a triptan.
16 . A method of alleviating the symptoms of or diminishing the extent of migraine in a subject, the method comprising:
a) administering a triptan to a subject; and
b) administering to a patient in need thereof, the crystalline Form I of claim 1 , or a pharmaceutical composition comprising thereof and a pharmaceutically acceptable excipient.
17 . The method of claim 16 , wherein the crystalline Form I or the pharmaceutical composition thereof and a pharmaceutically acceptable excipient is administered in the absence of the triptan.
18 . The method of claim 17 , wherein the triptan is sumatriptan, rizatriptan, naratriptan, zolmitriptan, eletriptan, almotriptan, frovatriptan, avitriptan, or donitriptan, or a pharmaceutically acceptable salt thereof.
19 . A method of treating neuropathic pain, the method comprising administering to a patient in need thereof, the crystalline Form I of claim 1 , or a pharmaceutical composition thereof and a pharmaceutically acceptable excipient.